Pazopanib and anti-VEGF therapy. - Wikidata - awgldk - TriplyDB

Pazopanib and anti-VEGF therapy.

Pazopanib and anti-VEGF therapy.

http://www.wikidata.org/entity/Q38160471

about

Pazopanib and anti-VEGF therapy.

http://www.wikidata.org/entity/Q38160471

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pazopanib and anti-VEGF therapy.

@en

type

label

Pazopanib and anti-VEGF therapy.

@en

prefLabel

Pazopanib and anti-VEGF therapy.

@en

P1433

Q38160471-29D499EC-82B0-4284-8907-14E40B14DEA3

P1476

Q38160471-AD5695EC-B789-4C1A-BE0C-63518A1B9CE2

P2093

Q38160471-691D1F9D-7503-432C-BDB8-1C924D8266F0

P2860

Q38160471-0176E58B-A357-40EF-BC2E-9C975C16CB2C

Q38160471-08F61E3E-2ADD-4FA9-85A0-90502CA37592

Q38160471-09A621B2-E97D-4C9B-A3D3-20F7CD9E15BA

Q38160471-0AE3FA99-15B3-4FCC-8268-BCBD7684BDF0

Q38160471-0F857820-2DEA-4BCB-AFCF-06803A8E650B

Q38160471-1310C2FD-0DDC-4C36-949F-C0F251294B5C

Q38160471-152D7173-C0F5-4232-B5A2-D1F524AB5C30

Q38160471-16FCD61D-BB45-4510-9F88-A1F00AF0BC77

Q38160471-1E9876E9-0158-4911-B5C1-E9BD5A8909DA

Q38160471-1E9C73C5-E454-4DFE-807C-6F2C09F6BCA6

P304

Q38160471-0CA8F3AC-7B2C-4AD0-8F6A-E38798845915

P31

Q38160471-76E0ED21-678F-42E3-9337-8AB05C0CC835

P478

Q38160471-2F9EE105-C0FE-4C11-8942-B626E2D2F837

P577

Q38160471-E9B69E91-5F36-47EC-981D-6C681C359EE4

P698

Q38160471-5DC8A74E-0130-4DA4-8BC9-16099790AFAF

P932

Q38160471-146F096E-DC48-4C08-B894-295741831F3E

P1433

Open Access Journal of Urology

P1476

Pazopanib and anti-VEGF therapy.

@en

P2093

Harry A Drabkin

http://www.w3.org/2001/XMLSchema#string

P2860

Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns

Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells

Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

P304

35-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24198612

http://www.w3.org/2001/XMLSchema#string

P932

3818876

http://www.w3.org/2001/XMLSchema#string